Cargando…
Stimulation programs for pediatric drug research – do children really benefit?
Most drugs that are currently prescribed in pediatrics have not been tested in children. Pediatric drug studies are stimulated in the USA by the pediatric exclusivity provision under the Food and Drug Administration Modernization Act (FDAMA) that grants patent extensions when pediatric labeling is p...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914295/ https://www.ncbi.nlm.nih.gov/pubmed/17225950 http://dx.doi.org/10.1007/s00431-006-0381-z |
_version_ | 1782134123053187072 |
---|---|
author | Boots, Isabelle Sukhai, Rám N. Klein, Richard H. Holl, Robert A. Wit, Jan M. Cohen, Adam F. Burggraaf, Jacobus |
author_facet | Boots, Isabelle Sukhai, Rám N. Klein, Richard H. Holl, Robert A. Wit, Jan M. Cohen, Adam F. Burggraaf, Jacobus |
author_sort | Boots, Isabelle |
collection | PubMed |
description | Most drugs that are currently prescribed in pediatrics have not been tested in children. Pediatric drug studies are stimulated in the USA by the pediatric exclusivity provision under the Food and Drug Administration Modernization Act (FDAMA) that grants patent extensions when pediatric labeling is provided. We investigated the effectiveness of these programs in stimulating drug research in children, thereby increasing the evidence for safe and effective drug use in the pediatric population. All drugs granted pediatric exclusivity under the FDAMA were analyzed by studying the relevant summaries of medical and clinical pharmacology reviews of the pediatric studies or, if these were unavailable, the labeling information as provided by the manufacturer. A systematic search of the literature was performed to identify drug utilization patterns in children. From July 1998 to August 2006, 135 drug entities were granted pediatric exclusivity. Most frequent drug groups were anti-depressants and mood stabilizers, ACE inhibitors, lipid-lowering preparations, HIV antivirals, and non-steroidal anti-inflammatory and anti-rheumatic drugs. The distribution of the different drugs closely matched the distribution of these drugs over the adult market, and not the drug utilization by children. Many drug studies in children have been performed since the introduction of the FDAMA. However, children infrequently use the drugs granted pediatric exclusivity. The priorities for pediatric drug research should be set by the need of the patients, not by market considerations. |
format | Text |
id | pubmed-1914295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-19142952007-07-12 Stimulation programs for pediatric drug research – do children really benefit? Boots, Isabelle Sukhai, Rám N. Klein, Richard H. Holl, Robert A. Wit, Jan M. Cohen, Adam F. Burggraaf, Jacobus Eur J Pediatr Original Paper Most drugs that are currently prescribed in pediatrics have not been tested in children. Pediatric drug studies are stimulated in the USA by the pediatric exclusivity provision under the Food and Drug Administration Modernization Act (FDAMA) that grants patent extensions when pediatric labeling is provided. We investigated the effectiveness of these programs in stimulating drug research in children, thereby increasing the evidence for safe and effective drug use in the pediatric population. All drugs granted pediatric exclusivity under the FDAMA were analyzed by studying the relevant summaries of medical and clinical pharmacology reviews of the pediatric studies or, if these were unavailable, the labeling information as provided by the manufacturer. A systematic search of the literature was performed to identify drug utilization patterns in children. From July 1998 to August 2006, 135 drug entities were granted pediatric exclusivity. Most frequent drug groups were anti-depressants and mood stabilizers, ACE inhibitors, lipid-lowering preparations, HIV antivirals, and non-steroidal anti-inflammatory and anti-rheumatic drugs. The distribution of the different drugs closely matched the distribution of these drugs over the adult market, and not the drug utilization by children. Many drug studies in children have been performed since the introduction of the FDAMA. However, children infrequently use the drugs granted pediatric exclusivity. The priorities for pediatric drug research should be set by the need of the patients, not by market considerations. Springer-Verlag 2007-01-17 2007-08 /pmc/articles/PMC1914295/ /pubmed/17225950 http://dx.doi.org/10.1007/s00431-006-0381-z Text en © Springer-Verlag 2007 |
spellingShingle | Original Paper Boots, Isabelle Sukhai, Rám N. Klein, Richard H. Holl, Robert A. Wit, Jan M. Cohen, Adam F. Burggraaf, Jacobus Stimulation programs for pediatric drug research – do children really benefit? |
title | Stimulation programs for pediatric drug research – do children really benefit? |
title_full | Stimulation programs for pediatric drug research – do children really benefit? |
title_fullStr | Stimulation programs for pediatric drug research – do children really benefit? |
title_full_unstemmed | Stimulation programs for pediatric drug research – do children really benefit? |
title_short | Stimulation programs for pediatric drug research – do children really benefit? |
title_sort | stimulation programs for pediatric drug research – do children really benefit? |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914295/ https://www.ncbi.nlm.nih.gov/pubmed/17225950 http://dx.doi.org/10.1007/s00431-006-0381-z |
work_keys_str_mv | AT bootsisabelle stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit AT sukhairamn stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit AT kleinrichardh stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit AT hollroberta stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit AT witjanm stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit AT cohenadamf stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit AT burggraafjacobus stimulationprogramsforpediatricdrugresearchdochildrenreallybenefit |